R&D overview

Aidea Pharma has an elite team led by senior experts in the industry. We always stay true to the mission of “dedicating for better medicine, pursuing greater success”, practice the value concept of “integrity, accountability, innovation and perseverance”, focus on the major diseases that seriously threaten human health, and have built R&D pipelines in the fields of anti-virus, anti-inflammation and cerebral stroke, and actively explore and develop innovative drugs taking the unmet clinical needs as orientation. 

R&D pipelines
  • 17
    17 major products under development
  • 29.97%
    R&D investment as a percentage of operation revenue
  • 16
    16 invention patents
  • 21
    21 utility model patents

Aidea Pharma focuses on major diseases such as virus infection, inflammation and cerebral stroke, comprehensively builds R&D pipelines by means of license-in and independent R&D, etc. There are currently 17 major products under development, focusing on 8 national class-I and 3 national class-II new drugs. The company is constantly actively investing in R&D, and the R&D investment as a percentage of operation revenue reached 29.97% in 2021. By the end of 2021, Aidea has submitted 62 patent applications and obtained 37 patents , including 16 invention patents and 21 utility model patents.